Commercial Insight: Antihormonal Cancer Therapies - Leading brands strive to minimize generic sales erosion now available at ReportsandReports

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) August 16, 2010 -- Dallas, TX: ReportsandReports announce it will carry Commercial Insight: Antihormonal Cancer Therapies - Leading brands strive to minimize generic sales erosion Market Research Report in its Store.

Browse complete Report on: http://www.reportsandreports.com/market-reports/commercial-insight-antihormonal-cancer-therapies-leading-brand/

Introduction

Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer. The high incidence of these tumor types translates into a significant commercial potential for drug developers. Collectively, the antihormonal therapy cancer brands generated sales of about $7.0 billion in the seven major pharmaceutical markets in 2009.

Scope

* In-depth analysis of the current and future antihormonal therapies market across the US, 5EU and Japan, plus a rest of world snapshot
* Antihormonal therapy sales forecasts for brands and generics from 2009 to 2019
* Assessment of the leading cancer brands and drug classes to identify key success factors within this sector
* Evaluation of the strategies of leading players in the antihormonals market

Highlights

The antihormonals market was worth $7.0 billion in 2009 across the seven major pharmaceutical markets. Datamonitor forecasts the antihormonals market will shrink marginally in the forecast period 20092019, at a CAGR of negative 0.7%.

In 2019 the top three brands in terms of forecast sales will be Arimidex, Lupron (leuprolide; Takeda/Abbott) and Casodex (bicalutamide; AstraZeneca). Despite losing around 54% of its current sales value to generic competitors, Arimidex will retain its market leading position.

In a mature market, the importance of product lifecycle management is high. AstraZeneca was the key player in the market in 2009, with an antihormonals portfolio valued at over $3.2 billion. With successful lifecycle management and a considerable investment in marketing activities, AstraZeneca has built a strong brand presence for its products.

Reasons to Purchase

* Quantify the performance of each of the marketed antihormonal therapy cancer brands in the seven major markets over the period 2009 to 2019
* Acquire a detailed account of antihormonal therapy cancer brand dynamics and the events that drive and limit their market growth
* Benchmark antihormonal therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot

About Us:

Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/

Antihormonal Cancer Therapies     Industry Analysis     market research reports     market share